This from YMB by No One Cares -- It's a must read

New Post Public Reply Private Reply Replies (1) Message Board
Dvb
679
This from YMB by No One Cares -- It's a must read IMHO.

Add this to the letter writing campaign...

I just finished reading your article entitled “What science has learned works and what doesn’t in COVID-19 treatments” and I must say how disappointed I am that the drug Leronlimab wasn’t mentioned. It has been shown in a recent Phase 3 clinical trial to reduce mortality at day 14 in critically ill COVID-19 patients 82 percent with a statistically significant p-value of 0.0233. Perhaps the timing of your article prevented its inclusion as these results were recently announced in late March but I strongly encourage you to explore this drug as a viable treatment option for critically ill COVID-19 patients. Our media landscape has done a disservice to millions of Americans by not publicizing the stellar results of this drug’s effects on this population of patients.

Here are a few other biases in favor of facts and science…
Leronlimab has been shown to reduce hospital stay by 5.5 days over the current standard of care (p=0.005). Critically ill COVID-19 patients who received Leronlimab were over five times more likely to be alive at day 14 than those who received standard of care only. In addition, it has an impeccable safety profile as there have been NO serious side effects in over 1,200 patients who were administered the drug across their HIV and COVID-19 clinical trials. None of the other treatments mentioned in your article have a similar safety record. You cover patient safety, correct? Why would you not cover this drug? Leronlimab can also be administered subcutaneously. The drug’s mechanism of action is unique in that it is not an anti-viral meaning that it works regardless of virus variant.

I also cannot help but take issue with including Remdesivir in your subtitle where you say “research is revealing medical interventions, such as Remdesivir, that help patients.” That is followed up in the article with the caveats “though the World Health Organization determined it did not prevent death or other bad outcomes.” and “As an antiviral, Remdesivir is likely to have its greatest effect in patients who are early in their disease course, before they are hospitalized. But the drug has to be given by infusion, rather than a shot or pill, making it impractical to deliver to patients who aren’t yet hospitalized.” Rather than supporting your initial statement, you leave the reader wondering if it works or at the very least, if it is a practical treatment option. Why give it such a prominent place in the subtitle when that statement is not supported by facts later in the article?

I really believe the true story to tell is one you may not have heard about. I hope you take my comments as they were intended, constructively, and really dig deep into Leronlimab. Perhaps an investigation into why Leronlimab has not been granted an Emergency Use Authorization (EUA) by our FDA and is now pursuing acceptance by the Philippine’s FDA (under pressure from their own doctors and government) to begin saving the lives of this fragile population of COVID-19 sufferers. It is a drug that has clinically proven to save lives and save money. That is the real treatment story to be told. I implore you to do your due diligence and tell it. Patients are counting on you and lives are at stake.
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 0

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Zunyi’s History Tour Carries China’s Story Overseas

Updated Category News Views 46

China’s national story does not travel overseas by accident; it gets carried by visitors, monuments, rail lines, rivers and carefully chosen questions. The Zunyi News and Media Center report follows Tayyab, a Pakistani PhD student in aerospace engineering at Peking University, as he heads from Beijing to Zunyi, Guizhou, carrying a copy of Edgar Snow’s Red Star Over...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 49

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 118

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Photocure Opens a New Access Route for Hexvix Patients

Updated Category News Views 25

Forty-plus markets just moved from “not available” toward a workable route for individual bladder cancer patients, and that is the real substance of Photocure’s new arrangement with Clinigen. This is not a sweeping product launch, nor is it an approval announcement dressed up in confetti. It is a Named Patient Program, which matters because the regulatory plumbing...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 171

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 65

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
CATL Makes Its APEC Case Beyond the Electric Car Market

Updated Category News Views 10

A 99-Second Pitch With Bigger Ambitions Battery swapping got a rare moment in the geopolitical sunlight at Shenzhen's APEC CEO Summit, and CATL was plainly trying to make that moment count. Dr. Robin Zeng, the company's founder, chairman and chief executive, used the opening business dialogue to argue that the Asia-Pacific region holds more opportunity than trouble. Fair...

Continue Reading
Diwali at Heritage Shows the Real Estate Community Test

Updated Category News Views 89

Fireworks do not sell a townhome by themselves, but belonging can sure help close the distance between a brochure and a serious purchase. Heritage at South Brunswick recently held a Diwali celebration sponsored by American Properties at South Brunswick LLC, bringing homeowners, families, and the builder's team into the same room for an evening of food, music, dancing,...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 321

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading

Top 5 Most Recently Viewed Articles

GRAX Honored as Cybersecurity Innovator by BostInno Awards

Updated Category News Views 66

GRAX Recognized as a Leader in Cybersecurity GRAX, Inc., well-known for its innovation in Salesforce data management and protection, has recently earned an esteemed recognition as a 2024 Fire honoree in cybersecurity from BostInno. This award celebrates companies that are driving innovation in the Boston area, emphasizing GRAX's role as a pioneer in data security....

Continue Reading
i2Cool and Marubeni Join Forces for Revolutionary Cooling Tech

Updated Category News Views 286

i2Cool and Marubeni Forge Strategic Partnership i2Cool, a pioneering company in the realm of electricity-free cooling technology, has established a significant global partnership with Marubeni, a prominent trading company from Japan. This collaboration is designed to facilitate the widespread adoption of electricity-free cooling technologies, concentrating particularly on...

Continue Reading
Jasper Therapeutics Upcoming Investor Conferencs - September 2024

Updated Category News Views 82

Jasper Therapeutics to Showcase Innovations at September Events Jasper Therapeutics, Inc. (NASDAQ: JSPR), a leader in biotechnology, is preparing for a series of investor conferences this September. The company is particularly excited to discuss briquilimab, an innovative antibody therapy designed to treat c-Kit (CD117) driven mast cell diseases, including chronic...

Continue Reading
Tech Sector Thrives as Meta Drives Nasdaq-100 to New Heights

Updated Category News Views 303

Tech Sector Soars with New Nasdaq-100 Records The Nasdaq-100 has reached an unprecedented high of 22,191.37, highlighting the unyielding strength of tech stocks. The renowned Invesco QQQ Trust (NASDAQ: QQQ) has also achieved a 52-week peak, reaching $540, demonstrating the energetic rally across the technology market. Meta Platforms Inc's Remarkable Performance Meta...

Continue Reading
Millicom Advances Infrastructure Sale and Special Dividend Plans

Updated Category News Views 207

Millicom Announces Infrastructure Deal Progress Millicom International Cellular S.A. (NASDAQ: TIGO) has made significant strides in its transaction with SBA Communications. The company recently revealed the partial closing of its sale involving LATI International S.A., the holding company for its mobile passive infrastructure assets in Central America. This deal has...

Continue Reading